ArticleMemorias do Instituto Oswaldo Cruz2025
A multicentre comparative study of serological methods for diagnosing Chagas disease in Brazil.
Article in Memorias do Instituto Oswaldo Cruz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Double-antigen sandwich ELISA based on chimeric antigens for detection of antibodies to Trypanosoma cruzi in human sera - A phase II study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Stage-InformedMicroorganisms · 2026Article
- A Rapid, Antigen-Independent Diagnostic Strategy for Chronic Chagas Disease Based on Serum ATR-FTIR Spectroscopy and Machine Learning.ACS omega · 2026Article
- Diagnostic performance of the TR Chagas Bio-Manguinhos rapid test for detecting anti-Trypanosoma cruzi IgG in human samples from three Southern Cone countries.PLoS neglected tropical diseases · 2026Article
- Evaluation of four chimeric Trypanosoma cruzi recombinant antigens for serological diagnosis of chronic Chagas disease in dogs: a phase II study.Parasites & vectors · 2025Article
- Diagnostic Performance of Chimeric Recombinant Antigens of Trypanosoma cruzi for Identifying Chagas Disease in Samples From Rio Grande do Sul.Tropical medicine & international health : TM & IH · 2025Article
- A New Approach for Chagas Disease Screening Using Serum Infrared Spectroscopy and Machine Learning Algorithms.ACS infectious diseases · 2025Article
- Evaluation of strategies for the diagnosis of Chagas disease in an endemic area: SaMi-Trop study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, remains a significant often underdiagnosed public health challenge in endemic regions, affecting millions globally. Accurate and timely diagnosis is critical, but the performance of existing diagnostic methods varies widely in sensitivity and specificity.
objectivesThis multicentre study assessed the diagnostic performance of 17 serological assays for detecting anti-T. cruzi antibodies.
methodsCommercial enzyme immunoassays (EIA), indirect haemagglutination assays (IHA), indirect immunofluorescence assays (IIF), rapid diagnostic tests (RDT), and a chemiluminescent microparticle immunoassay (CMIA) were included in this study.
findingsSome EIA-based tests achieved 100% sensitivity, while IHAs and IIFs demonstrated reduced specificity. CMIA exhibited 100% sensitivity, highlighting its potential as a robust screening tool. Combining EIAs with IHAs or IIFs improved overall sensitivity, often surpassing 99%, although specificity remained variable. Cross-reactivity with other parasitic diseases posed challenges to specificity, particularly in assays employing crude antigens. MAIN
conclusionsThese findings emphasise the importance of tailoring diagnostic tool selection to regional epidemiological contexts and advancing antigen refinement to enhance diagnostic accuracy and accessibility, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.